Joseph J. Ferra Jr. - 16 Jun 2024 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Jun 2024, 16:15:10 UTC
Prior SEC filing
19 Mar 2024
Next SEC filing
18 Sep 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Robert Yang, Attorney-in-Fact

Key filing fact

Joseph J. Ferra Jr. filed Form 4 for Elevation Oncology, Inc. (ELEV) on 18 Jun 2024.

Key facts

  • This page summarizes Joseph J. Ferra Jr.'s Form 4 filing for Elevation Oncology, Inc. (ELEV).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Jun 2024, 16:15.

Change

  • Previous filing in this sequence was filed on 19 Mar 2024.
  • Current net transaction value: -$14,948.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELEV transaction

Common Stock

Options Exercise

Transaction value
Shares
+12,562
Change %
+15%
Price
Shares after
98,242
Date
16 Jun 2024
Ownership
Direct
Footnotes
F1
ELEV transaction

Common Stock

Tax liability

Transaction value
$14,948
Shares
-4,628
Change %
-4.7%
Price
$3.23
Shares after
93,614
Date
16 Jun 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELEV transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-12,562
Change %
-20%
Price
$0.000000
Shares after
50,247
Date
16 Jun 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,562
Exercise price
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

25% of the RSUs vested on June 16, 2022, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F3

The RSUs do not expire; they either vest or are canceled prior to the vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .